Following these proofs-of-concept experiments, we will now look for the effect of an immunotherapy anti-PD-1 or anti-CTLA-4 [27] to monitor the impact on tumor cell immunotoxicity after adding autologous lymphocytes. This evidence concerns the gene PDCD1 and neoplasm.